View in EDS

Belzutifan efficacy in von Hippel-Lindau disease-associated renal cell carcinoma versus natural history control arm.

Saved in:

Bibliographic Details
Title:	Belzutifan efficacy in von Hippel-Lindau disease-associated renal cell carcinoma versus natural history control arm.
Authors:	Linehan WM; Urologic Oncology Branch, National Cancer Institute, Bethesda, MD, United States., Jemielita T; Biostatistics and Research Decision Sciences, Merck & Co., Inc, Rahway, NJ, United States., Cornell J; Biostatistics and Research Decision Sciences, Merck & Co., Inc, Rahway, NJ, United States., Chen K; Biostatistics and Research Decision Sciences, Merck & Co., Inc, Rahway, NJ, United States., Ball MW; Urologic Oncology Branch, National Cancer Institute, Bethesda, MD, United States., Srinivasan R; Urologic Oncology Branch, National Cancer Institute, Bethesda, MD, United States., Liu Y; Clinical Research, Merck & Co., Inc, Rahway, NJ, United States., Perini RF; Clinical Research, Merck & Co., Inc, Rahway, NJ, United States., Pinto CA; Biostatistics and Research Decision Sciences, Merck & Co., Inc, Rahway, NJ, United States.
Source:	Journal of the National Cancer Institute [J Natl Cancer Inst] 2026 Jun 01; Vol. 118 (6), pp. 1081-1088.
Publication Type:	Journal Article
Journal Info:	Publisher: Oxford University Press Country of Publication: United States NLM ID: 7503089 Publication Model: Print Cited Medium: Internet ISSN: 1460-2105 (Electronic) Linking ISSN: 00278874 NLM ISO Abbreviation: J Natl Cancer Inst Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1460-2105
DOI:	10.1093/jnci/djag064